No. PAR-25-248 · National Institutes of Health
Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
- Award range
- Not specified
- Expected awards
- Not specified
- Application deadline
- Oct 8, 2027
- Posted
- Nov 21, 2024
- Last verified
- Yesterday
At a glance
AI summaryThis funding announcement supports research on cancer causes and early detection biomarkers using PLCO biospecimens and data, including pre-diagnostic blood samples and, for some cancers, tissue microarrays. Applicants may be nonprofits, universities, governments, for-profit organizations, small businesses, and foreign organizations, and foreign components of U.S. organizations are allowed. Awards are made through a cooperative agreement; application budgets are not limited, the project period can be up to 5 years, and cost sharing is not required. Clinical trials are not allowed, and applications must include a letter confirming PLCO specimen availability; if outside biospecimens are used, a letter approving access is also required.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.
Who can apply
- City or township governments
- County governments
- For-profit organizations other than small businesses
- Independent school districts
- Native American tribal governments (Federally recognized)
- Native American tribal organizations (other than Federally recognized)
- Nonprofits with 501(c)(3) status (other than higher education)
- Nonprofits without 501(c)(3) status (other than higher education)
- Others
- Private institutions of higher education
- Public and State controlled institutions of higher education
- Public housing authorities / Indian housing authorities
- Small businesses
- Special district governments
- State governments
Program history
USASpending.govAssistance listing 93.393 · Cancer Cause and Prevention Research
Real awards this federal program has made — the whole assistance listing (93.393), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 167 | $596,996 | $422,899 – $685,984 |
| FY 2025 | 233 | $743,438 | $397,772 – $1,287,560 |
| FY 2024 | 331 | $1,232,605 | $403,858 – $1,928,145 |
| FY 2023 | 333 | $1,580,141 | $399,888 – $2,324,497 |
| FY 2022 | 371 | — | — |
| FY 2021 | 317 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 1,752 — award counts are complete.
- HEALTH RESEARCH, INC. $8,975,418 · FY 2023
- REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE $7,529,016 · FY 2024
- WAKE FOREST UNIVERSITY HEALTH SCIENCES $7,411,948 · FY 2023
- VANDERBILT UNIVERSITY MEDICAL CENTER $7,120,874 · FY 2023
- REGENTS OF THE UNIVERSITY OF MINNESOTA $6,827,635 · FY 2023
Source: USASpending.gov · refreshed Aug 14, 2026